Calliditas Therapeutics AB (Calliditas Therapeutics AB) Cash-to-Debt

: 1.01 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Calliditas Therapeutics AB's cash to debt ratio for the quarter that ended in Dec. 2023 was 1.01.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Calliditas Therapeutics AB could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Calliditas Therapeutics AB's Cash-to-Debt or its related term are showing as below:

CALT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.81 Med: 122.03 Max: No Debt
Current: 1.01

During the past 9 years, Calliditas Therapeutics AB's highest Cash to Debt Ratio was No Debt. The lowest was 0.81. And the median was 122.03.

CALT's Cash-to-Debt is ranked worse than
76.82% of 1540 companies
in the Biotechnology industry
Industry Median: 6.495 vs CALT: 1.01

Calliditas Therapeutics AB Cash-to-Debt Historical Data

The historical data trend for Calliditas Therapeutics AB's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Calliditas Therapeutics AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

No Debt

1,134.58

4.48

1.71

1.01

Calliditas Therapeutics AB Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Cash-to-Debt																1.58	1.71	1.11	1.02	1.01

Competitive Comparison

For the Biotechnology subindustry, Calliditas Therapeutics AB's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Calliditas Therapeutics AB Cash-to-Debt Distribution

For the Biotechnology industry and Healthcare sector, Calliditas Therapeutics AB's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Calliditas Therapeutics AB's Cash-to-Debt falls into.

Calliditas Therapeutics AB Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Calliditas Therapeutics AB's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	94.928	/	(0	+	94.232)
	=	1.01

Calliditas Therapeutics AB's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	94.928	/	(0	+	94.232)
	=	1.01

Calliditas Therapeutics AB (NAS:CALT) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Calliditas Therapeutics AB Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Calliditas Therapeutics AB's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Calliditas Therapeutics AB (Calliditas Therapeutics AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calliditas Therapeutics AB (NAS:CALT) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

CALTX:Sweden CALTXs:UK LC8:Germany

Address

Kungsbron 1, D5, Stockholm, SWE, SE-111 22

Website

https://www.calliditas.se

Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.